Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International AB has announced an upcoming presentation of its interim report for January to September 2025, scheduled for October 29, 2025. The presentation will be led by CEO Martin Welschof and CFO Stefan Ericsson, providing insights into the company’s financial performance and ongoing clinical programs. Stakeholders can participate via webcast or teleconference, highlighting BioInvent’s commitment to transparency and engagement with investors and analysts.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel antibodies for cancer immuno-modulatory therapy. The company is engaged in Phase 1/2 trials for hematological cancer and solid tumors, leveraging its proprietary F.I.R.S.T technology platform to identify targets and antibodies. BioInvent generates revenue through research collaborations, license agreements with top-tier pharmaceutical companies, and antibody production for third parties.
YTD Price Performance: -27.79%
Average Trading Volume: 86,449
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.83B
Find detailed analytics on BINV stock on TipRanks’ Stock Analysis page.